Assertio (ASRT) Competitors $0.66 -0.03 (-3.70%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.68 +0.01 (+2.23%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. CRDF, FENC, VOR, INBX, CGC, LIMN, ESPR, BTMD, NBTX, and PRQRShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Cardiff Oncology (CRDF), Adherex Technologies (FENC), Vor Biopharma (VOR), Inhibrx Biosciences (INBX), Canopy Growth (CGC), Liminatus Pharma (LIMN), Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Its Competitors Cardiff Oncology Adherex Technologies Vor Biopharma Inhibrx Biosciences Canopy Growth Liminatus Pharma Esperion Therapeutics biote Nanobiotix ProQR Therapeutics Cardiff Oncology (NASDAQ:CRDF) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Which has higher earnings & valuation, CRDF or ASRT? Assertio has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$680K403.09-$45.43M-$0.92-4.48Assertio$124.96M0.51-$21.58M-$0.32-2.06 Do analysts rate CRDF or ASRT? Cardiff Oncology presently has a consensus price target of $11.70, suggesting a potential upside of 183.98%. Assertio has a consensus price target of $2.75, suggesting a potential upside of 316.48%. Given Assertio's stronger consensus rating and higher probable upside, analysts plainly believe Assertio is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in CRDF or ASRT? 16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 4.0% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, CRDF or ASRT? Cardiff Oncology has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Does the media prefer CRDF or ASRT? In the previous week, Assertio had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Assertio and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.65 beat Assertio's score of -0.09 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is CRDF or ASRT more profitable? Assertio has a net margin of -25.72% compared to Cardiff Oncology's net margin of -8,308.50%. Assertio's return on equity of -24.87% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-8,308.50% -76.45% -62.85% Assertio -25.72%-24.87%-10.87% SummaryAssertio beats Cardiff Oncology on 11 of the 16 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.68M$2.44B$5.61B$9.29BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-2.069.1428.5419.58Price / Sales0.51679.15429.2495.01Price / Cash13.97164.3436.0257.93Price / Book0.524.608.145.54Net Income-$21.58M$30.99M$3.24B$257.73M7 Day Performance-3.96%-1.81%0.18%-0.08%1 Month Performance1.58%5.73%5.96%8.09%1 Year Performance-62.27%-7.03%26.24%13.02% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio1.8396 of 5 stars$0.66-3.7%$2.75+316.5%-57.1%$65.68M$124.96M-2.0620News CoverageCRDFCardiff Oncology1.2399 of 5 stars$3.65-0.3%$9.88+170.5%+64.1%$243.49M$680K0.0020FENCAdherex Technologies2.4576 of 5 stars$8.47-3.8%$13.00+53.5%+33.2%$242.88M$47.54M0.0010News CoverageVORVor BiopharmaN/A$2.67+39.8%N/AN/A$238.67MN/A0.00140News CoverageGap UpINBXInhibrx Biosciences2.4497 of 5 stars$18.35+12.4%N/A+65.7%$236.39M$200K0.14166High Trading VolumeCGCCanopy Growth0.4041 of 5 stars$1.20-6.3%$2.00+66.7%-84.7%$235.35M$225.65M0.003,150LIMNLiminatus PharmaN/A$6.93-23.2%N/AN/A$234.65MN/A0.00N/AGap DownESPREsperion Therapeutics3.941 of 5 stars$1.11-5.1%$7.00+530.6%-54.8%$231.89M$332.31M-1.39200Analyst RevisionBTMDbiote3.2334 of 5 stars$3.99-5.5%$8.00+100.5%-52.0%$230.88M$197.19M6.49194Positive NewsNBTXNanobiotix2.3233 of 5 stars$4.75-2.5%$8.00+68.6%-3.4%$229.54M$39.18M0.00100PRQRProQR Therapeutics2.3666 of 5 stars$2.14-1.8%$8.00+273.8%+34.9%$229.36M$20.46M0.00180 Related Companies and Tools Related Companies Cardiff Oncology Competitors Adherex Technologies Competitors Vor Biopharma Competitors Inhibrx Biosciences Competitors Canopy Growth Competitors Liminatus Pharma Competitors Esperion Therapeutics Competitors biote Competitors Nanobiotix Competitors ProQR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASRT Stock Alerts